This study is to describe the real-world treatment patterns and clinical outcomes in moderate-to-severe AD patients receiving abrocitinib over a 12-month observation period, and to describe patient demographic and baseline characteristics.
Patients aged ≥12 years
Patients with confirmed diagnosis of moderate-to-severe AD as assessed by the physician
Patients for whom the physician's decision has been made to newly prescribe abrocitinib in usual clinical practice conditions
Evidence of a personally signed and dated informed consent/assent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study
Any prior use of abrocitinib
Simultaneous participation in a study that includes administration of any investigational drug or procedure
Pfizer
Lead sponsor